Executive Order 14336, signed Aug. 13, 2025, directs the Department of Health and Human Services to fill the Strategic Active Pharmaceutical Ingredients Reserve, a stockpile of the biologically active components of medicines. The order was published in the Federal Register on Aug. 19, 2025.
The order puts the work mainly on the Office of the Assistant Secretary for Preparedness and Response, known as ASPR, which is part of the department. According to the order, active pharmaceutical ingredients are the components of finished drugs that act on the body. It says only about 10 percent of those ingredients, by volume, for drugs used in the United States are made here. It also says nearly two in five finished prescription drug products are made in this country.
The order directs ASPR to develop, within 30 days of the order’s date, a list of about 26 drugs that are especially critical to the nation’s health and security interests. ASPR must consult agencies that have scientific expertise, as well as the Assistant to the President for Economic Policy and the Assistant to the President and Homeland Security Advisor. It must also give the Director of the Office of Management and Budget an accounting of existing, available funds that could pay for opening the reserve and for a 6-month supply of ingredients.
The order says the Office of Management and Budget is to help the Secretary of Health and Human Services repurpose available funds, consistent with law. The order does not state a dollar amount.
Within 120 days, and subject to the availability of those funds, ASPR must take all measures to ready the existing reserve repository so it can receive and maintain the ingredients. The order then directs ASPR to obtain a 6-month supply of the ingredients needed for the critical drugs, preferring domestically made ingredients if possible. The ingredients must be placed in the repository no later than 30 days after ASPR certifies it as ready.
A second part of the order covers other essential medicines. Within 90 days, ASPR must give the economic policy adviser, the homeland security adviser and the budget office an update to its 2022 list of 86 essential medicines and medical countermeasures. It must include a plan to obtain, store and maintain a 6-month supply of ingredients for drugs on the updated list that are not already covered by the critical drug list. The order says to obtain them from domestic manufacturers where possible.
That plan must also include a proposal and cost estimate for opening a second reserve repository in the United States within one year of the order’s date.
The order refers to Executive Order 13944 of Aug. 6, 2020, which dealt with essential medicines made in the United States. It does not revoke or amend that order.
Under its general provisions, the order does not affect the authority that law gives to any agency or its head. It also does not affect the budget director’s functions on budget, administrative or legislative proposals. It says the order is to be carried out consistent with applicable law and subject to the availability of appropriations. It states that it creates no legal rights or benefits enforceable against the United States. The costs of publishing the order are to be paid by the Department of Health and Human Services.